 This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria is designed to provide data on an AH7N9 vaccine made with HA antigen derived from the influenza AShanghai22013 virus. 